Hikma and Junshi Biosciences sign exclusive licensing agreement for cancer treatment drug toripalimab for the Middle East and North Africa region

miscellaneous news
By:
On:

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces a new exclusive licensing and commercialization agreement with Junshi Biosciences, an innovation-driven biopharmaceutical company, for toripalimab in the Middle East and North Africa (MENA). Under the terms of the agreement, Hikma has an exclusive license toContinue Reading